Los Angeles Capital Management & Equity Research Inc. Invests $226,000 in Aclaris Therapeutics Inc (ACRS)
Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,340 shares of the biotechnology company’s stock, valued at approximately $226,000.
Several other hedge funds have also made changes to their positions in the company. Millennium Management LLC acquired a new position in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $291,000. MetLife Investment Advisors LLC acquired a new position in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $244,000. Alps Advisors Inc. grew its holdings in shares of Aclaris Therapeutics by 21.1% in the first quarter. Alps Advisors Inc. now owns 41,369 shares of the biotechnology company’s stock valued at $725,000 after purchasing an additional 7,201 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Aclaris Therapeutics in the first quarter valued at approximately $234,000. Finally, Trexquant Investment LP acquired a new position in shares of Aclaris Therapeutics in the first quarter valued at approximately $354,000.
In related news, Director Stephen A. Tullman bought 6,250 shares of the stock in a transaction dated Wednesday, August 15th. The stock was acquired at an average price of $15.97 per share, for a total transaction of $99,812.50. Following the acquisition, the director now owns 163,757 shares in the company, valued at approximately $2,615,199.29. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Kamil Ali-Jackson sold 5,000 shares of the company’s stock in a transaction on Tuesday, June 12th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the insider now owns 82,536 shares of the company’s stock, valued at approximately $1,650,720. The disclosure for this sale can be found here. Corporate insiders own 17.00% of the company’s stock.
Shares of Aclaris Therapeutics stock opened at $15.45 on Friday. Aclaris Therapeutics Inc has a 12-month low of $14.11 and a 12-month high of $28.93. The firm has a market capitalization of $493.52 million, a PE ratio of -6.18 and a beta of 1.31.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.04. Aclaris Therapeutics had a negative net margin of 1,584.99% and a negative return on equity of 49.45%. The business had revenue of $3.68 million during the quarter, compared to analysts’ expectations of $2.76 million. sell-side analysts expect that Aclaris Therapeutics Inc will post -4.54 earnings per share for the current year.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
See Also: Book Value Per Share in Stock Trading
Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics Inc (NASDAQ:ACRS).
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.